Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
Status:
Completed
Trial end date:
2015-09-15
Target enrollment:
Participant gender:
Summary
Given the disappointing results with routine ASCT in t(4;14) patients, we propose this open
label phase II study of bortezomib along with dexamethasone and pegylated liposomal
doxorubicin (Doxil/Caelyx), referred to as the DBd regimen, for 4 cycles, followed by
post-induction therapy with cyclophosphamide + bortezomib + prednisone (referred to as the
CyBorP regimen) for 8 cycles. Since patients with t(4;14) remain at high risk for relapse,
maintenance therapy with dexamethasone weekly will be given until disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Ortho Biotech, Inc. Princess Margaret Hospital, Canada